Brief communication
Long-term follow-up of efficacy and safety of megavoltage radiotherapy in high-risk giant cell tumors of bone

https://doi.org/10.1016/0360-3016(95)00159-VGet rights and content

Abstract

Purpose: Giant cell tumours of the bone are rare and have variable presentations and natural history. There may be significant functional sequelae as a result of their locally aggressive nature or as a result of treatment. We reviwed the long-term results of radiotherapy for high risk giant cell tumours to assess: The efficacy of radiotherapy and the potential late toxicity of treatment, and to determine indications for radiation treatment.

Methods and materials: This report is a retrospective review of 21 localized giant cell tumors of the bone treated with radiotherapy between 1959 and 1991. Radiation was used in the primary management of 13 cases adn for recurrent disease in eight cases. In the primary cases, two received radiotherapy as the sole modality (including a massive pelvic lesion and an advanced maxillary sinus tumor with orbital adn pterygoid invasion), and in the other 11, 3 had gross residual disease following surgery and 8 had microscopic residual disease. Of eight recurrent cases, five were treated with radiotherapy alone and three with combined surgery and radiation. Sites of origin included extremity bones in nine cases, pelvis in six, spine in four, and skull in two. Extraosseous disease was apparent in 18 tumours and extended to contiguous structures in 14 (including four cases of spinal cord compression, three cases of sacral plexopathy, and one patient with temporal lobe invasion). The most common dose regimen was 35 Gy/15 frations/3 weeks (14 cases), with varying schedules for the remainder.

Results: Mean follow-up time was 15.4 years (2 to 35 years). Local control was achieved in 29 of 21 patients with radiotherapy. The two failures were subsequently salvaged for an ultimate control rate of 100%. One of the two radiotherapy failures was a marginal failure and was subsequently salvated with combined surgery and radiotherapy. No patient died of giant cell tumor. Radiotherapy was well tolerated, with no serious late toxicity. There were no cases of malignant transformation or radiation-induced cancer.

Conclusion: Long-term results in this series indicate taht radiotherapy in modest doses (35 Gy in 15 fractions or equivalent) is a safe and effective option for primary and recurrent giant cell tumors of the bone. Radiotherapy shouldb e used if surgery would result in significant functional morbidity and should be considered in select sites where the probability of recurrence is higha dn there is potential for significant mobidity from tumour relapse or subsequent surgery.

References (12)

There are more references available in the full text version of this article.

Cited by (81)

  • FDG PET/CT in bone sarcomas

    2022, Nuclear Medicine and Molecular Imaging: Volume 1-4
  • Osteoclast-rich lesions of bone: A clinical and molecular overview

    2021, Bone Cancer: Bone Sarcomas and Bone Metastases - From Bench to Bedside
  • Reconstruction giant cell tumor of the right proximal humerus Campanacci 3 with pedicle and rod system: A case report

    2018, International Journal of Surgery Case Reports
    Citation Excerpt :

    This has led surgeons to enhance their surgical procedure with use of chemical or physical adjuvants such as liquid nitrogen, acrylic cement, phenol, hydrogen peroxide, locally delivered chemotherapy, or radiation therapy [16,17]. The latter has been linked with malignant transformation in the past but the risk of this complication has been recently challenged and may be different with modern radiotherapy modalities [18]. Local adjuvant therapy has been shown to be useful in controlling recurrence rates (Fig. 6).

  • A case of giant cell tumor of the temporal bone

    2015, Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology
  • Osteoclast-rich lesions of bone: A clinical and molecular overview

    2015, Bone Cancer: Primary Bone Cancers and Bone Metastases: Second Edition
View all citing articles on Scopus

Presented at the 36th Annual Meeting of the American Society of Therapeutic Radiology and Oncology, San Francisco, CA, October 6, 1994.

View full text